

ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111
(619) 329-3999 | ils-lab.com

CJC-1295 (No DAC) + Ipamorelin - 10mg

Tested for: Kovalabs

PASS

COA #: COA-2026-BGB51X
Lot Number: CI10-292
Accession #: ACC-2026-16031
Labeled Content: 10mg

Analysis Date: 08/18/2026
Appearance: Good
Sample Matrix: Lyophilized
Volume: 3mL
Date Received: 08/14/2026



Scan to verify
authenticity at ils-lab.com
Access Code: E4QN6UFJ

Method: Blend Purity, Identity & Quantitation (HPLC)

Identity

CJC-1295 (No DAC) + Ipamorelin

Peptide Purity

99.67%



Fentanyl
Free


Blend Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.67%	%	PASS
Net Blend Peptide Content	Report Only	10.33	mg	N/A
-- CJC-1295 (No DAC)		5.17	mg	
-- Ipamorelin		5.17	mg	
Identity (HPLC-RTM)	CJC-1295 (NO DAC) + IPAMORELIN	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS



CJC-1295 (No DAC) + Ipamorelin
10mg - CI10-292

HPLC Chromatogram



CJC-1295 (No DAC) + Ipamorelin 10mg - CI10-292: UV Chromatogram

Notes & Methodology

- Date Tested: 08/18/2026. Methods: Blend Purity, Identity & Quantitation (HPLC).
- The sample was confirmed to be CJC-1295 (No DAC) + Ipamorelin by HPLC. Identification by chromatographic retention time comparison with a reference standard.
- Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.
- Per-component content calculated from total net peptide content using the manufacturer's stated formulation ratio (CJC-1295 (No DAC), Ipamorelin). All components confirmed present by HPLC identity testing, unless explicitly stated otherwise.
- This certificate reports analytical results for the sample(s) submitted to ILS Laboratories for testing. All sample identifications, product names, brand names, lot/batch numbers, and labeled content are provided by the submitting party and have not been independently verified. Results reflect only the analytical testing of the specific sample(s) provided and do not constitute an evaluation or endorsement of the manufacturer's processes, quality systems, or overall production. ILS Laboratories makes no representations regarding the intended use, safety, efficacy, regulatory status, or intellectual property ownership of any materials tested.



Dr. Greg Kalyuzhny

Dr. Greg Kalyuzhny
Lab Director
8/20/2026

COA #: COA-2026-BGB51X
Access Code: E4QN6UFJ
Verify: <portal.ils-lab.com/verify/60ju2IZ3-6kkgIDZ>
Issued: 8/20/2026